Cover Image
市場調查報告書

Jiangsu Hansoh Pharmaceutical Co., Ltd.的產品平台分析

Jiangsu Hansoh Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321949
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Jiangsu Hansoh Pharmaceutical Co., Ltd.的產品平台分析 Jiangsu Hansoh Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 30 Pages
簡介

Jiangsu Hansoh Pharmaceutical Co., Ltd.是總公司設立於中國的製藥企業,從事學名藥及醫藥有效成分(API)的研究開發,製造,批發。其對像領域有抗癌藥,糖尿病治療藥,中樞神經系統醫藥品,腸胃系統醫藥品,抗生劑等5個領域。

本報告提供Jiangsu Hansoh Pharmaceutical Co., Ltd.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Jiangsu Hansoh Pharmaceutical Co., Ltd.的基本資料

  • Jiangsu Hansoh Pharmaceutical Co., Ltd.概要
  • 主要資訊
  • 企業資料

Jiangsu Hansoh Pharmaceutical Co., Ltd.:R&D概要

  • 主要的治療範圍

Jiangsu Hansoh Pharmaceutical Co., Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Jiangsu Hansoh Pharmaceutical Co., Ltd.:開發中產品概況

  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Jiangsu Hansoh Pharmaceutical Co., Ltd.:藥物簡介

  • desvenlafaxine succinate SR
  • iloperidone
  • azilsartan
  • cafusertib hydrochloride
  • Small Molecule for Respiratory Disease

Jiangsu Hansoh Pharmaceutical Co., Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Jiangsu Hansoh Pharmaceutical Co., Ltd.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07161CDB

Summary

Global Markets Direct's, 'Jiangsu Hansoh Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Jiangsu Hansoh Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Jiangsu Hansoh Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Jiangsu Hansoh Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Jiangsu Hansoh Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Jiangsu Hansoh Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Jiangsu Hansoh Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Jiangsu Hansoh Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Jiangsu Hansoh Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Jiangsu Hansoh Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. Snapshot
    • Jiangsu Hansoh Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Drug Profiles
    • flumatinib mesylate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Thymalfasin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • desvenlafaxine succinate SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EPO-018B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • iloperidone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • azilsartan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cafusertib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Respiratory Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Analysis
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Target
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Jiangsu Hansoh Pharmaceutical Co., Ltd., Key Information
  • Jiangsu Hansoh Pharmaceutical Co., Ltd., Key Facts
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Partnered Products in Pipeline, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Phase III, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Phase II, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Phase I, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Discovery, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015

List of Figures

  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Jiangsu Hansoh Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top